Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2022

View Archived Issues

MAO mutant zebrafish exhibit abnormal brain development

ATR kinase blockade useful for treating pancreatic ductal adenocarcinoma

Idorsia Pharmaceuticals discovers Kv7 potassium channel activators

Charite-Universitaetsmedizin Berlin, Sapreme Technologies present new saponin derivatives

New kappa-opioid receptor agonists identified at Humanwell Pharmaceutical US

Ortho-hIL-2/ortho-hIL-2Rbeta pair enhances antitumor efficacy of engineered T cells

Yes targeting useful for treatment of HCC, researchers suggest

Sodium salt of a quinoline derivative shows anticancer efficacy in vivo

Once-daily dermal administration of Epoladerm well tolerated in four preclinical studies

Eisbach Bio and MD Anderson partner to target synthetic lethality in cancer

ProMIS initiates program to develop monoclonal antibodies to treat schizophrenia

BetterLife reports data from in vivo oral bioavailability and food-effect PK study with BETR-001

Evotec and Lilly collaborate on drug discovery for metabolic diseases

Almirall and IRB Barcelona collaborate on molecular glue degraders for skin diseases

NT-I7 promotes longer survival in murine models of glioma through CD8+ T cells

Subcutaneous nanocarrier-mediated delivery of rapamycin

Amyloid aggregates differ in familial and sporadic AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...